<DOC>
	<DOCNO>NCT01487317</DOCNO>
	<brief_summary>The aim study evaluate efficacy anticholinesterase treatment patient age 75 , hospitalize delirium . Study type : Interventional Study design : randomize , double-blind , placebo-controlled study one month 11-month follow-up</brief_summary>
	<brief_title>Rivastigmine Management Delirium</brief_title>
	<detailed_description>Delirium affect 50 % hospitalized patient age 75 . Delirium increase risk comorbid illness , hospital length stay , institutionalization , death . Patients diagnose undiagnosed cognitive impairment risk develop delirium . In prospective study , half elderly patient delirium see emergency department cognitive impairment . Hypothesis : cholinesterase inhibitor reduce duration severity delirium Main objective : - ass efficacy cholinesterase inhibitor patient age 75 hospitalized delirium Secondary objective : - describe one year percentage patient diagnosis Alzheimer 's disease associate disorder - ass sensitivity cholinesterase inhibitor sub-group patient diagnosis dementia one year Design method Multicenter , randomize , control study two parallel arm : rivastigmine group placebo group . The study include treatment period one month follow-up 11 month . Evaluation delirium severity conduct DRS-R98 severity day hospitalization . At day 14 , accord DRS-R98 severity score , interruption treatment upward dose titration At day 30 , last treatment ( active placebo ) administration evaluation CAM , DRS-R98 severity , MMSE DSM IV dementia criterion . In case dementia diagnosis , investigator ( MD ) identify etiologic diagnosis . At month 3 12 , evaluation CAM , DRS-R98 severity , MMSE DSM IV dementia criterion , number consultation hospitalization . In case dementia diagnosis , , investigator ( MD ) identify etiologic diagnosis .</detailed_description>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Patients age 75 Hospitalization delirium correlate surgery le 48 hour Patients delirium require presence feature 1 ( acute onset fluctuation course ) , 2 ( inattention ) , 3 ( disorganize thinking ) 4 ( alter level consciousness ) Confusion Assessment Model DRS R98 &gt; 10 Absence contraindication cholinesterase inhibitor treatment Health insurance affiliation Having sign informed consent form Caregiver/informant provide information patient Use IAchE memantine medication Contraindication IAchE medication Frontotemporal dementia Diseases involve shortterm survival Digestive bleeding Ischemic hemorrhagic stroke related actual onset ( include hemorrhagic contusion ) Natremia â‰¤120 mmol/l time hospitalization Post epileptic confusion Hepatocellular failure Cardiorespiratory impairment risk transfer intensive care unit Major sensory deficit could interfere cognitive assessment ( visual auditory ) Not fluent French Being guardianship Absence caregiver/informant sign inform consent form</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Delirium</keyword>
	<keyword>acetylcholinesterase inhibitor</keyword>
	<keyword>Elderly</keyword>
	<keyword>Emergency department</keyword>
</DOC>